Teva Receives European Marketing Authorization for ZOELY™ Oral Contraceptive

Teva Pharmaceutical Industries Ltd

announced today that its new oral contraceptive, ZOELY™ (NOMAC/E2 –nomegestrol acetate 2.5 mg/17β-estradiol 1.5 mg), has received a Marketing Authorization in the European Union (

) for the prevention of pregnancy. This clears the way to allow the product to be launched in Europe by the end of 2011. Unlike currently available contraceptive pills, ZOELY™ is a combined oral contraceptive tablet containing a unique monophasic combination of 2 steroid hormones; 17-beta estradiol, an estrogen that is structurally identical to the major estrogen produced by the ovaries of healthy non-pregnant women, and nomegestrol acetate, a highly selective progesterone-derived progestin. This innovative combination will be made available in a convenient 24 day active and 4 day placebo dosing regimen.